Equity Overview
Price & Market Data
Price: $2.55
Daily Change: +$0.419 / 16.42%
Range: $2.13 - $2.55
Market Cap: $59,731,864
Volume: 1,641,168
Performance Metrics
1 Week: 46.47%
1 Month: 126.4%
3 Months: 128.4%
6 Months: 139.4%
1 Year: 126.4%
YTD: 107.5%
Company Details
Employees: 15
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.